Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of FCF Margin data on file, last reported at 41.01% in Q1 2026.

• On a quarterly basis, FCF Margin fell 1728.0% year-over-year to 41.01% in Q1 2026; TTM through Mar 2026 was 24.53%, a 4270.0% increase from a year earlier, with the FY2025 full-year figure at 27.68%, up 5267.0% from the prior year.
• FCF Margin for Q1 2026 stood at 41.01%, down from 49.86% in the prior quarter.
• Over the last five years, FCF Margin for AKBA reached as high as 49.86% in Q4 2025 and fell as low as 23228.95% in Q1 2022.
• Historically, FCF Margin has averaged 1376.73% across 5 years, with a median of 19.48% in 2022.
• Across the five-year window, FCF Margin sank 2309629 bps in 2022 and surged 2317808 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 98.02% in 2022, then soared by 111 bps to 10.44% in 2023, then sank by 179 bps to 8.2% in 2024, then jumped by 708 bps to 49.86% in 2025, then plunged by 182 bps to 41.01% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 41.01% in Q1 2026, 49.86% in Q4 2025, and 47.69% in Q3 2025.